Microbiotica: CASE STUDY

2025-01-16T14:21:41+00:001 December 2024|

Based originally upon the research of the human microbiome carried out at the Wellcome Sanger Institute, Microbiotica was spun out as a microbiome therapeutics company in 2016. Today, Microbiotica is advancing steadily towards introducing transformational microbiome-based therapeutics and biomarkers in areas of high medical need, with first clinical trials – underpinned by a landmark £50m investment during 2022 – starting soon.

Congenica: CASE STUDY

2025-06-24T16:46:17+01:0016 January 2024|

Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres, and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

Kymab: CASE STUDY

2025-06-24T16:44:53+01:0012 January 2024|

Kymab was a therapeutic antibody company based in Cambridge, UK, developing novel solutions in drug and vaccine development. Using its unique technology with roots in the laboratories of the Wellcome Sanger Institute, the company developed broad diversity, high-quality human antibodies. Kymab's therapeutics were designed to modulate the immune system to overcome cancer immune tolerance and to treat autoimmune diseases.

COSMIC: CASE STUDY

2026-10-23T15:08:20+01:0010 January 2024|

COSMIC is an online catalogue of somatic mutations in cancer, a gold standard data resource of global impact in the field of cancer genomics. The database has utility for basic research into the mechanisms of cancer but is also relevant for pharmaceutical R&D activities in oncology as well as the development of products and services in cancer diagnosis and patient stratification.